Last reviewed · How we verify
NOX-A12
At a glance
| Generic name | NOX-A12 |
|---|---|
| Also known as | olaptesed pegol, olaptesed |
| Sponsor | TME Pharma AG |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer (PHASE2)
- Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients (PHASE1, PHASE2)
- Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer (PHASE1, PHASE2)
- NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL) (PHASE2)
- NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma (PHASE2)
- NOX-A12 Multiple Ascending Dose Study in Healthy Volunteers (PHASE1)
- NOX-A12 First-in-human (FIH) Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NOX-A12 CI brief — competitive landscape report
- NOX-A12 updates RSS · CI watch RSS
- TME Pharma AG portfolio CI